JAC Advance Access originally published online on March 31, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 793-796
© 2004 The British Society for Antimicrobial Chemotherapy
Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae
1 Department of Medical Microbiology, Medical School, University of Edinburgh, Edinburgh EH8 9AG, UK; 2 Aventis Pharma Ltd, Kings Hill, West Malling, Kent ME19 4AH, UK
Received 31 October 2003; returned 28 December 2003; revised 2 February 2004; accepted 10 February 2004
Objectives: The first objective was to investigate the in vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents. The second objective was to identify the influence of the erm(B) and mef(A) genes on the susceptibility of Streptococcus pneumoniae to telithromycin.
Methods: The in vitro activity of telithromycin against S. pneumoniae, Moraxella catarrhalis and Haemophilus influenzae, isolated from the UK and 40 macrolide-resistant S. pneumoniae from four different countries was compared with a variety of antimicrobial agents. The 140 isolates were examined for the presence of the erm(B) and mef(A) genes. The impact of 5% CO2 on susceptibility testing was also investigated.
Results: Telithromycin showed greatest activity against S. pneumoniae, but also had good activity against M. catarrhalis and H. influenzae, which was independent of their resistance profiles to other antibiotics. The MIC90 of telithromycin for S. pneumoniae was 0.12 mg/L, which was 64-fold lower than the lowest macrolide MIC; 21% of the S. pneumoniae were macrolide resistant. Thirty-eight per cent of the macrolide-resistant strains were erm(B)-positive and 62% were mef(A)-positive, but no strain contained both genes. The activity of telithromycin was similar to that of azithromycin against both M. catarrhalis and H. influenzae, Erythromycin was slightly less active: 1% and 8% of M. catarrhalis and H. influenzae, respectively, were resistant to erythromycin, but none were resistant to telithromycin. Five per cent of the S. pneumoniae strains and 4% of the H. influenzae strains changed from telithromycin susceptible to non-susceptible entirely because of the incubation conditions. The MIC50s and MIC90s of S. pneumoniae, M. catarrhalis and H. influenzae increased by one dilution when incubated in CO2.
Conclusions: Telithromycin has shown high in vitro activity against S. pneumoniae, including those strains that are macrolide susceptible and resistant as well as M. catarrhalis and H. influenzae. This study has also demonstrated that there is no cross-resistance between erythromycin and telithromycin. The impact of 5% CO2 on susceptibility testing should be investigated further before providing definite guidelines on telithromycin susceptibility testing.
Keywords: resistance, erm(B), ketolides
* Corresponding author. Tel: +44-131-650-8270; Fax: +44-131-651-1385; E-mail: fwalsh{at}staffmail.ed.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Turner, G. R. Corey, and E. Abrutyn Telithromycin. Ann Intern Med, March 21, 2006; 144(6): 447 - 448. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Faccone, P. Andres, M. Galas, M. Tokumoto, A. Rosato, and A. Corso Emergence of a Streptococcus pneumoniae Clinical Isolate Highly Resistant to Telithromycin and Fluoroquinolones J. Clin. Microbiol., November 1, 2005; 43(11): 5800 - 5803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Bouchillon, J. L. Johnson, D. J. Hoban, T. M. Stevens, and B. M. Johnson Impact of carbon dioxide on the susceptibility of key respiratory tract pathogens to telithromycin and azithromycin J. Antimicrob. Chemother., July 1, 2005; 56(1): 224 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Zhanel, C. Johanson, N. Laing, T. Hisanaga, A. Wierzbowski, and D. J. Hoban Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1943 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kasbekar and P. S. Acharya Telithromycin: The first ketolide for the treatment of respiratory infections Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Batard, M. E. Juvin, C. Jacqueline, D. Bugnon, J. Caillon, G. Potel, and H. B. Drugeon Influence of Carbon Dioxide on the MIC of Telithromycin for Streptococcus pneumoniae: an In Vitro-In Vivo Study Antimicrob. Agents Chemother., January 1, 2005; 49(1): 464 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, C. Johanson, T. Hisanaga, C. Mendoza, N. Laing, A. Noreddin, A. Wierzbowski, and D. J. Hoban Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations J. Antimicrob. Chemother., December 1, 2004; 54(6): 1072 - 1077. [Abstract] [Full Text] [PDF]
|
|